Not actual patients.
Not actual health care providers.
Financial support for patients is available. One simple plan covers copays and deductibles. Plus, patients are automatically reenrolled January 1 of each year.
Eligible, commercially insured patients may pay as low as $0 per prescription*
Offering savings up to
$6,000 per year
To enroll patients in the NGENLA Copay Program,
visit the Pfizer Bridge Copay Portal at PfizerBridgeCopay.com.
*Eligibility required. Annual savings up to $6,000. State and federal beneficiaries not eligible. Terms and conditions apply; see below.
TERMS AND CONDITIONS
By using this copay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, or a state prescription drug assistance program. Patient must have private insurance. Offer is not valid for cash paying patients. Patients are responsible for as little as a $0 monthly copayment based upon program utilization. The value of this copay card is limited to a maximum of $6,000 per calendar year. This copay card is not valid when the entire cost of the prescription drug is eligible to be reimbursed by the patient’s private insurance plan or other private health or pharmacy benefit programs. Patients must deduct the value of this copay card from any reimbursement request submitted to their private insurance plan, either directly by patients or on their behalf. Patients are responsible for reporting use of the copay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the copay card, as may be required. Patients should not use the copay card if their insurer or health plan prohibits use of manufacturer copay cards. This copay card is not valid where prohibited by law. This copay card cannot be combined with any other savings, free trial or similar offer for the specified prescription. This copay card will be accepted only at participating pharmacies. If the patient’s pharmacy does not participate, the patient may be able to submit a request for a rebate in connection with this offer. This copay card is not health insurance. Offer good only in the U.S. (excluding Puerto Rico, the U.S. Virgin Islands, and Guam). This copay card is limited to 1 per person during this offering period and is not transferable. A copay card may not be redeemed more than once per 30 days per patient. No other purchase is necessary. No membership fee. Data related to redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify the patient. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Offer expires 12/31/2023. For more information, visit our website www.NGENLA.com, call 1-800-645-1280 or visit Pfizer.com. NGENLA Copay Program, PO Box 220746, Charlotte, NC 28222-0746.
Assistance may be available for eligible uninsured patients or patients with public insurance who meet all other eligibility criteria.
If your insurance coverage is delayed or denied due to certain circumstances, the NGENLA Interim Care program may be able to help. Eligible, commercially insured patients enrolled in the NGENLA Interim Care program may receive NGENLA at no cost from 30 days up to a maximum of 180 days depending on the type of coverage delay.† Contact the Pfizer Bridge Program at 1-800-645-1280 for more information once your health care provider has decided that NGENLA is right for you.
Interim care must be requested by the physician. Patients must meet program criteria to receive the support. Interim care support can range from 30 days to a maximum of 180 days depending on the type of coverage delay. Commercially insured patients only and may not reside in Massachusetts, Michigan, Minnesota, or Rhode Island.
Interim Care is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for NGENLA. For patients who experience a delay in insurance coverage while actively pursuing a prior authorization or appeal, coverage may be up to a maximum of 90 days. For patients who experience a delay due to a new to market block, coverage may be up to a maximum of 180 days. Interim Care is not available to patients covered under Medicaid, Medicare or other federal or state healthcare insurance programs.
This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
© 2023 Pfizer Inc. All rights reserved. PP-SMT-USA-0115
This confirms that you will soon be receiving weekly dosing reminders for NGENLA.
Growth hormone should not be used in children after the growth plates have closed.
Growth hormone should not be used in children with some types of eye problems caused by diabetes (diabetic retinopathy).
Growth hormone should not be used in children who have cancer or other tumors.
Growth hormone should not be used in children who are critically ill because of some types of heart or stomach surgery, trauma, or breathing (respiratory) problems.
Growth hormone should not be used in children with Prader-Willi syndrome who are very overweight or have breathing problems including sleep apnea.
NGENLA should not be used by children who have had an allergic reaction to somatrogon-ghla or any of the ingredients in NGENLA. Look for prompt medical attention in case of an allergic reaction.
Some children have developed diabetes mellitus while taking growth hormone. Dosages of diabetes medicines may need to be adjusted during treatment with NGENLA. Children should be watched carefully if NGENLA is given along with glucocorticoid therapy and/or other drugs that are processed by the body in the same way.
In childhood cancer survivors, treatment with growth hormone may raise the likelihood of a new tumor, particularly some benign (non-cancerous) brain tumors. This likelihood may be higher in children who were treated with radiation to the brain or head. Your child’s health care provider will need to check your child for a return of cancer or a tumor.
Children treated with growth hormone have had increased pressure in the brain. If your child has headaches, eye problems, nausea (feeling like you are going to be sick), or vomiting, contact your child’s health care provider.
NGENLA may decrease thyroid hormone levels. Decreased thyroid hormone levels may change how well NGENLA works. Your child’s health care provider will do blood tests to check your child’s hormone levels.
Children treated with growth hormone should be checked regularly for low serum cortisol levels and/or the need to increase the dose of the glucocorticoids they are taking.
In children experiencing fast growth, curvature of the spine may develop or worsen. This is also called scoliosis. Children with scoliosis should be checked regularly to make sure their scoliosis does not get worse during their growth hormone therapy.
Use a different area on the body for each injection. This can help to avoid skin problems such as lumpiness or soreness.
Growth hormone treatment may cause serious and constant stomach (abdominal) pain. This could be a sign of pancreatitis. Tell your child’s health care provider if your child has any new stomach (abdominal) pain.
In studies of NGENLA in children with GHD, side effects included injection site reactions such as pain, swelling, rash, itching, or bleeding. Other side effects were the common cold, headache, fever (high temperature), low red blood cells (anemia), cough, vomiting, decreased thyroid hormone levels, stomach pain, rash, or throat pain.
A health care provider will help you with the first injection. He or she will also train you on how to inject NGENLA.
NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).